Search Results - "Gaidano, G."

Histologic transformation in marginal zone lymphomas by Conconi, A., Franceschetti, S., Aprile von Hohenstaufen, K., Margiotta-Casaluci, G., Stathis, A., Moccia, A.A., Bertoni, F., Ramponi, A., Mazzucchelli, L., Cavalli, F., Gaidano, G., Zucca, E.

“…Histologic transformation (HT) is a poorly understood event in patients with marginal zone lymphoma (MZL). The aim of this study was to analyze incidence and…”
Get full text

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation by Malcikova, J., Tausch, E., Rossi, D., Sutton, L. A., Soussi, T., Zenz, T., Kater, A. P., Niemann, C. U., Gonzalez, D., Davi, F., Gonzalez Diaz, M., Moreno, C., Gaidano, G., Stamatopoulos, K., Rosenquist, R., Stilgenbauer, S., Ghia, P., Pospisilova, S.

“…In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with…”
Get full text

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma by Jurczak, W., Zinzani, P.L., Gaidano, G., Goy, A., Provencio, M., Nagy, Z., Robak, T., Maddocks, K., Buske, C., Ambarkhane, S., Winderlich, M., Dirnberger-Hertweck, M., Korolkiewicz, R., Blum, K.A.

“…This two-stage, phase IIa study investigated the antitumor activity and safety of MOR208, an Fc-engineered, humanized, CD19 antibody, in patients with relapsed…”
Get full text

Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia by Arruga, F, Gizdic, B, Serra, S, Vaisitti, T, Ciardullo, C, Coscia, M, Laurenti, L, D'Arena, G, Jaksic, O, Inghirami, G, Rossi, D, Gaidano, G, Deaglio, S

“…The purpose of this study was to compare the expression and function of NOTCH1 in chronic lymphocytic leukemia (CLL) patients harboring a wild-type (WT) or…”
Get full text

Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR by Chng, W-J, Goldschmidt, H, Dimopoulos, M A, Moreau, P, Joshua, D, Palumbo, A, Facon, T, Ludwig, H, Pour, L, Niesvizky, R, Oriol, A, Rosiñol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Gillenwater, H H, Mohamed, N, Feng, S, Aggarwal, S, Hájek, R

“…The randomized phase 3 study ENDEAVOR demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for…”
Get full text

Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22 by Arruga, F, Gizdic, B, Bologna, C, Cignetto, S, Buonincontri, R, Serra, S, Vaisitti, T, Gizzi, K, Vitale, N, Garaffo, G, Mereu, E, Diop, F, Neri, F, Incarnato, D, Coscia, M, Allan, J, Piva, R, Oliviero, S, Furman, R R, Rossi, D, Gaidano, G, Deaglio, S

“…Even if NOTCH1 is commonly mutated in chronic lymphocytic leukemia (CLL), its functional impact in the disease remains unclear. Using CRISPR/Cas9-generated…”
Get full text

Recurrent mutations refine prognosis in chronic lymphocytic leukemia by Baliakas, P, Hadzidimitriou, A, Sutton, L-A, Rossi, D, Minga, E, Villamor, N, Larrayoz, M, Kminkova, J, Agathangelidis, A, Davis, Z, Tausch, E, Stalika, E, Kantorova, B, Mansouri, L, Scarfò, L, Cortese, D, Navrkalova, V, Rose-Zerilli, M J J, Smedby, K E, Juliusson, G, Anagnostopoulos, A, Makris, A M, Navarro, A, Delgado, J, Oscier, D, Belessi, C, Stilgenbauer, S, Ghia, P, Pospisilova, S, Gaidano, G, Campo, E, Strefford, J C, Stamatopoulos, K, Rosenquist, R

“…Through the European Research Initiative on chronic lymphocytic leukemia (CLL) (ERIC), we screened 3490 patients with CLL for mutations within the NOTCH1 ( n…”
Get full text

The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma by Piva, R, Deaglio, S, Famà, R, Buonincontri, R, Scarfò, I, Bruscaggin, A, Mereu, E, Serra, S, Spina, V, Brusa, D, Garaffo, G, Monti, S, Dal Bo, M, Marasca, R, Arcaini, L, Neri, A, Gattei, V, Paulli, M, Tiacci, E, Bertoni, F, Pileri, S A, Foà, R, Inghirami, G, Gaidano, G, Rossi, D

Get full text

Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment‐related risk factors by Ruggeri, M., Tosetto, A., Palandri, F., Polverelli, N., Mazzucconi, M. G., Santoro, C., Gaidano, G., Lunghi, M., Zaja, F., De Stefano, V., Sartori, R., Fazi, P., Rodeghiero, F.

“…Summary Background An increased risk of thrombosis has been reported in primary immune thrombocytopenia (ITP) and with the use of thrombopoietin (TPO) receptor…”
Get full text

The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi by Luminari, S., Biasoli, I., Arcaini, L., Versari, A., Rusconi, C., Merli, F., Spina, M., Ferreri, A.J.M., Zinzani, P.L., Gallamini, A., Mastronardi, S., Boccomini, C., Gaidano, G., D'Arco, A.M., Di Raimondo, F., Carella, A.M., Santoro, A., Musto, P., Federico, M.

“…The role of [18F] fluorodeoxyglucose (FDG)-positron emission tomography (PET) in follicular lymphoma (FL) staging is not yet determined. The aim of the present…”
Get full text

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study by Moreau, P, Joshua, D, Chng, W-J, Palumbo, A, Goldschmidt, H, Hájek, R, Facon, T, Ludwig, H, Pour, L, Niesvizky, R, Oriol, A, Rosiñol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Gillenwater, H H, Mohamed, N, Aggarwal, S, Feng, S, Dimopoulos, M A

“…The randomized phase 3 ENDEAVOR study ( N =929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma…”
Get full text

NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation by Pozzo, F, Bittolo, T, Arruga, F, Bulian, P, Macor, P, Tissino, E, Gizdic, B, Rossi, F M, Bomben, R, Zucchetto, A, Benedetti, D, Degan, M, D'Arena, G, Chiarenza, A, Zaja, F, Pozzato, G, Rossi, D, Gaidano, G, Del Poeta, G, Deaglio, S, Gattei, V, Dal Bo, M

“…In chronic lymphocytic leukemia (CLL), NOTCH1 mutations have been associated with clinical resistance to the anti-CD20 rituximab, although the mechanisms…”
Get full text

High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists by De Stefano, V, Ruggeri, M, Cervantes, F, Alvarez-Larrán, A, Iurlo, A, Randi, M L, Elli, E, Finazzi, M C, Finazzi, G, Zetterberg, E, Vianelli, N, Gaidano, G, Rossi, E, Betti, S, Nichele, I, Cattaneo, D, Palova, M, Ellis, M H, Cacciola, R, Tieghi, A, Hernandez-Boluda, J C, Pungolino, E, Specchia, G, Rapezzi, D, Forcina, A, Musolino, C, Carobbio, A, Griesshammer, M, Sant’Antonio, E, Vannucchi, A M, Barbui, T

“…The optimal duration of treatment with vitamin K antagonists (VKA) after venous thromboembolism (VTE) in patients with Philadelphia-negative myeloproliferative…”
Get full text

NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components by Pozzo, F, Bittolo, T, Vendramini, E, Bomben, R, Bulian, P, Rossi, F M, Zucchetto, A, Tissino, E, Degan, M, D’Arena, G, Di Raimondo, F, Zaja, F, Pozzato, G, Rossi, D, Gaidano, G, Del Poeta, G, Gattei, V, Dal Bo, M

“…In chronic lymphocytic leukemia (CLL), the mechanisms controlling cell growth and proliferation in the presence of NOTCH1 mutations remain largely unexplored…”
Get full text

NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL by DEL GIUDICE, Ilaria, ROSSI, Davide, GUARINI, Anna, GAIDANO, Gianluca, FOA, Robin, CHIARETTI, Sabina, MARINELLI, Marilisa, TAVOLARO, Simona, GABRIELLI, Sara, LAURENTI, Luca, MARASCA, Roberto, RASI, Silvia, FANGAZIO, Marco

“…Trisomy 12, the third most frequent chromosomal aberration in chronic lymphocytic leukemia (CLL), confers an intermediate prognosis. In our cohort of 104…”
Get full text

Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients by De Stefano, V, Vannucchi, A M, Ruggeri, M, Cervantes, F, Alvarez-Larrán, A, Iurlo, A, Randi, M L, Pieri, L, Rossi, E, Guglielmelli, P, Betti, S, Elli, E, Finazzi, M C, Finazzi, G, Zetterberg, E, Vianelli, N, Gaidano, G, Nichele, I, Cattaneo, D, Palova, M, Ellis, M H, Cacciola, E, Tieghi, A, Hernandez-Boluda, J C, Pungolino, E, Specchia, G, Rapezzi, D, Forcina, A, Musolino, C, Carobbio, A, Griesshammer, M, Barbui, T

“…We retrospectively studied 181 patients with polycythaemia vera ( n =67), essential thrombocythaemia ( n =67) or primary myelofibrosis ( n =47), who presented…”
Get full text

Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial by Ladetto, M, Tavarozzi, R, Zanni, M, Evangelista, A, Ferrero, S, Tucci, A, Botto, B, Bolis, S, Volpetti, S, Zilioli, V R, Puccini, B, Arcari, A, Pavone, V, Gaidano, G, Corradini, P, Tani, M, Cavallo, F, Milone, G, Ghiggi, C, Pinto, A, Pastore, D, Ferreri, A J M, Latte, G, Patti, C, Re, F, Benedetti, F, Luminari, S, Pennese, E, Bossi, E, Boccomini, C, Anastasia, A, Bottelli, C, Ciccone, G, Vitolo, U

“…Optimal consolidation for young patilents with relapsed/refractory (R/R) follicular lymphoma (FL) remains uncertain in the rituximab era, with an unclear…”
Get more information

Viruses and lymphoma by Gaidano, G

Get more information

NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways by Benedetti, D, Tissino, E, Pozzo, F, Bittolo, T, Caldana, C, Perini, C, Martorelli, D, Bravin, V, D’Agaro, T, Rossi, F M, Bomben, R, Santinelli, E, Zaja, F, Pozzato, G, Chiarenza, A, Di Raimondo, F, Del Poeta, G, Rossi, D, Gaidano, G, Dal Bo, M, Gattei, V, Zucchetto, A

“…In chronic lymphocytic leukemia (CLL), stabilizing mutations of NOTCH1 , affecting up to 10–15% of cases, have been associated to poor prognosis, disease…”
Get full text

The miR-17 similar to 92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes by Bomben, R, Gobessi, S, Dal Bo, M, Volinia, S, Marconi, D, Tissino, E, Benedetti, D, Zucchetto, A, Rossi, D, Gaidano, G, Del Poeta, G, Laurenti, L, Efremov, D G, Gattei, V

“…Chronic lymphocytic leukemia (CLL) cells from clinically aggressive cases have a greater capacity to respond to external microenvironmental stimuli, including…”
Get full text